1. Generics Bulletin

Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats

Indian Firm’s Rituxan Biosimilar Added Amid Pegfilgrastim Frustrations

 
• By Dean Rudge

The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.

high jump
Kabi is hoping soon to get over its pegfilgrastim hurdle • Source: Alamy

Fresenius Kabi has in-licensed exclusive US commercialization rights to Dr Reddy’s Laboratories proposed biosimilar Rituxan/MabThera (rituximab) product, as the German firm once again pushed back its expectations for its biosimilars business to break even at the EBITDA level.

The move broadens the German firm’s pipeline and offers a further near-term opportunity, amid continued delays in the US for its proposed pegfilgrastim biosimilar, Stimufend, that have

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products